(1)
Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively
Tumor burden decrease observed in eight of 15 refractory unresectable mCRC patients, including six of nine patients at the highest dose level of 1x10
9 cells per infusion
Emergence of new T cell clones in the peripheral blood T cell repertoire four months after therapy was observed in patients analyzed from the highest dose level who experienced either a confirmed partial response or stable disease suggesting that modulation of the endogenous immune response may be an important mechanism of action of CYAD-101 in mCRC patients
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
Genmab A/SJanuary 13, 2021 GMT
Company Announcement
Milestone triggered by progress in Phase 3 study of epcoritamab in diffuse large B-cell lymphoma
Copenhagen, Denmark; January 13, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that it has reached the first milestone in its collaboration with AbbVie. A USD 40 million milestone payment was triggered by the first patient dosed in the Phase 3 study of subcutaneous epcoritamab versus investigator’s choice of chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
THERADIAG Signs a Contract to Supply ORGENTEC With Quality Control Reagents Called Alegria Check
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in
in vitro diagnostics and theranostics, today announces that it has signed an partnership contract with ORGENTEC, a German company that is a leader on the global autoimmunity market, to provide it with quality control reagents called Alegria Check.
Medical analysis laboratories are having to comply with increasingly stringent regulatory requirements in terms of quality control. Theradiag has developed expertise in quality control products over many years. To meet these growing demands, Theradiag will manufacture and supply ORGENTEC, from 2021 and for at least the next three years, with multiparametric quality controls enabling the Alegria system s performances to be monitored. Alegria is a fully automatic analytical instrument developed by ORGENTEC for the diagnosis of autoimmune disorders and infec
22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company’s Reduced Nicotine Content Cigarettes Company will significantly increase planting in the 2021 crop year 22nd Century Group, Inc Williamsville, New York, UNITED STATES
WILLIAMSVILLE, N.Y., Jan. 12, 2021 (GLOBE NEWSWIRE) 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that the Company will significantly expand its growing program for VLN
® reduced nicotine content tobacco based on the Company’s latest sales projections. This new planting for VLN